APPLICATION OF S1P RECEPTOR AGONIST AND METHOD OF TREATMENT, ALLEVIATION OR RETARDATION OF OPTIC NEURITIS OR DEMYELINATING DISEASES PROGRESSION Russian patent published in 2010 - IPC A61K31/135 A61K39/395 A61K38/21 A61K38/19 A61P25/00 

FIELD: medicine.

SUBSTANCE: invention relates to medication and deals with application of 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol in free form or in form of pharmaceutically acceptable salt, or phosphate FTY720 in manufacturing medication for treatment, alleviation or retardation of optic neurosis progression. Also described is method of treatment, alleviation or retardation of optic neurosis progression in patient, who needs it, which includes introduction to said patient of therapeutically efficient quantity of 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol in free form or in form of pharmaceutically acceptable salt, or phosphate FTY720 or therapeutically effective quality of a) 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol or its phosphate in free form or in form of pharmaceutically acceptable salt, and b) at least one associated agent, which is selected from group consisting of interferons and mTor inhibitors.

EFFECT: invention is aimed at extension of arsenal of means for treatment of optic neurosis.

9 cl, 3 ex